Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-7.22||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||0.14%||Sales Growth - Q/Q||-0.66%||P/E||-15.06|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.78%||ROE||-13.25%||ROI|
|Current Ratio||8.11||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-294.47%||Net Profit Margin||-247.3%||Dividend Payout Ratio|
|Cash From Financing Activities||2.46 M||Cash From Investing Activities||-192.98 M||Cash From Operating Activities||-24.16 M||Gross Profit|
|Net Profit||-24.79 M||Operating Profit||-24.93 M||Total Assets||533.82 M||Total Current Assets||340.84 M|
|Total Current Liabilities||42.01 M||Total Debt||Total Liabilities||59.32 M||Total Revenue||6.34 M|
|High 52 week||233.05||Low 52 week||91.25||Last close||149.91||Last change||14.16%|
|RSI||64.09||Average true range||5.8||Beta||1.74||Volume||513.89 K|
|Simple moving average 20 days||12.23%||Simple moving average 50 days||25.91%||Simple moving average 200 days||4.02%|
|Performance Week||9.4%||Performance Month||22.09%||Performance Quart||28.83%||Performance Half||-7.23%|
|Performance Year||-24.63%||Performance Year-to-date||51.12%||Volatility daily||3.75%||Volatility weekly||8.38%|
|Volatility monthly||17.18%||Volatility yearly||59.51%||Relative Volume||135.56%||Average Volume||682.46 K|
|New High||New Low|
2019-03-25 08:24:04 | Massachusetts concern details plan to hire new workers in Durham
2019-03-23 09:30:01 | Why Is Bluebird BLUE Up 15.3% Since Last Earnings Report?
2019-03-12 10:30:05 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-03-12 10:07:02 | Celgene CELG Submits Application for MS Drug in Europe
2019-03-11 02:28:17 | Here's Why bluebird bio Gained 16.3% in February
2019-03-08 08:00:00 | bluebird bio to Present at Investor Conferences in March
2019-03-07 12:32:45 | What Are Analysts Saying About bluebird bio, Inc.’s NASDAQ:BLUE Earnings Outlook?
2019-03-05 08:04:11 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-02-26 16:21:00 | With a Stocked War Chest, bluebird bio Presses On
2019-02-26 11:15:04 | Biotech ETFs Jump on Roche-Spark Deal
2019-02-23 20:10:00 | Better Buy: bluebird bio vs. Gilead Sciences
2019-02-22 14:46:07 | bluebird BLUE Q4 Earnings Beat Estimates, Revenues Up Y/Y
2019-02-21 19:15:12 | Bluebird Bio BLUE Reports Q4 Loss, Tops Revenue Estimates
2019-02-21 18:17:36 | Bluebird: 4Q Earnings Snapshot
2019-02-14 07:55:00 | Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext — New Horizons, Emerging Trends, and Upcoming Developments
2019-02-13 10:31:03 | Earnings Preview: Bluebird Bio BLUE Q4 Earnings Expected to Decline
2019-02-12 09:11:02 | AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
2019-02-11 06:30:00 | bluebird bio Appoints Chip Baird as Chief Financial Officer
2019-02-08 08:03:15 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-02-06 13:52:06 | Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
2019-02-01 14:11:36 | German firm that serves gene therapy biotechs opens Cambridge HQ
2019-01-31 11:46:04 | Celgene CELG Q4 Earnings Beat Estimates, Revenues Up Y/Y
2019-01-31 07:55:00 | Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics
2019-01-28 11:52:03 | Did bluebird bio, Inc. NASDAQ:BLUE Insiders Sell Shares?
2019-01-24 10:12:00 | Where Will bluebird bio Be in 5 Years?
2019-01-23 10:48:03 | 5 Best Biotech Bets Likely to Outperform Estimates in Q4
2019-01-22 11:50:00 | Here's Why CRISPR Therapeutics Stock Fell Today
2019-01-22 08:06:14 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-01-21 14:00:00 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-01-15 08:03:53 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-01-12 09:41:00 | Here's What Pushed bluebird bio Stock Down 44.3% in 2018
2019-01-12 07:31:00 | 3 Biotech Stocks to Watch in 2019
2019-01-11 06:55:00 | Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical
2019-01-10 08:01:00 | Three tech, three biotech companies that are top takeover targets in 2019
2019-01-09 08:02:03 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-01-08 19:33:16 | Biotech Proposes Paying for Pricey Drugs by Installment
2019-01-08 17:31:10 | Celgene CELG Provides Guidance for 2019, Updates Pipeline
2019-01-04 12:16:00 | Here's Why bluebird bio Shares Got Knocked Down 19.3% in December
2019-01-04 12:05:02 | How Celgene Is Positioned Now
2019-01-04 10:13:37 | Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout
2019-01-04 10:01:03 | Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
2019-01-03 10:30:00 | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-01-03 08:00:00 | bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
2019-01-02 16:00:02 | How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
2019-01-02 14:30:02 | A Financial Overview of Sangamo Therapeutics in December 2018